Desvenlafaxine
Pristiq · Khedezla · Pristiq Extended-Release
Serotonin-Norepinephrine Reuptake InhibitorGeneric availableTDM data
The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective SNRI.
Compare Desvenlafaxine →FDA-Approved Indications
- Major depressive disorder (adults)
Common Off-Label Uses
- Vasomotor symptoms (menopause)
- Generalized anxiety disorder
- Neuropathic pain
What Sets This Drug Apart
- Active metabolite of venlafaxine with more consistent SNRI pharmacology across all doses — no dose-dependent serotonin-to-norepinephrine shift
- 50 mg is both the starting and therapeutic dose; trials showed no additional benefit above 50 mg, simplifying dosing
- Minimal CYP involvement: not a CYP2D6 substrate or meaningful inhibitor, unlike venlafaxine — preferred when CYP2D6 drug interactions are a concern
- CYP2D6 genetic variation does not influence clinical response (unlike venlafaxine, which requires CYP2D6 for metabolic activation)
- FDA-approved for MDD only — does not carry venlafaxine's GAD, SAD, or Panic Disorder indications
- May be particularly useful for vasomotor symptoms (hot flushes) in perimenopausal women
Boxed Warning
SUICIDAL THOUGHTS AND BEHAVIORS